Oxford BioMedica PLC (OXBDF)

[marcusl2]

Novartis Q3 Results:
Kymriah (USD 79 million) strong demand continued and sales increased primarily driven by ongoing uptake in the US and Europe. There are over 160 qualified treatment centers and more than 20 countries worldwide that have coverage for at least one indication. Reimbursement for DLBCL was received in Scotland and for both pediatric ALL and DLBCL in Italy.

HTTPS://www.novartis.com/sites/www.novartis.com/files/2019-10-interim-financial-report-en.pdf

Excellent $79 m ( $58 Q2 ). I make that a 36% increase in just 3 months.

Then in 2021 it will be available for 1st relapse and in FL.

Hopefully China approval soon.


We could possibly see full year sales of $400m + by the end of 2020.

Nice royalties and manufacturing profits for OXB.